Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer

Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer

There is a great need for non-invasive tools that inform of an early molecular response to cancer therapeutic treatment. Here, we tested the hypothesis that proteolytically resistant proteins could be candidate circulating tumor biomarkers for cancer therapy. Proteins resistant to proteolysis are dr...

Full description

Bibliographic Details
Main Authors: Mercè Juliachs, Mireia Pujals, Chiara Bellio, Nathalie Meo-Evoli, Juan M. Duran, Esther Zamora, Mireia Parés, Anna Suñol, Olga Méndez, Alex Sánchez-Pla, Francesc Canals, Cristina Saura, Josep Villanueva
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
manganese superoxide dismutase (SOD2)
response biomarkers
breast cancer
secretome
Online Access:https://www.mdpi.com/2072-6694/14/16/3858

Similar Items

Similar Items